Clinical trials: Associated Conditions

Motion Sickness

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

• Completed
• Age: 18 to 70 years
• Phase 3

This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion

Trial name

NCT04947423

Testing

DPI-386 Nasal Gel

Where

United States

Volunteers

140 people, healthy volunteers welcome

Sponsor

Repurposed Therapeutics, Inc.